800
Participants
Start Date
January 31, 2017
Primary Completion Date
August 17, 2022
Study Completion Date
March 31, 2023
Nivolumab
Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Tegafur-gimeracil-oteracil potassium
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Oxaliplatin
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Placebo
Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Anhui Province Clinical Site, Anhui Province
Beijing Clinical Site1, Beijing
Beijing Clinical Site2, Beijing
Cuangdong Province Clinical Site, Cuangdong Province
Guangdong Province Clinical Site1, Guangdong Province
Guangdong Province Clinical Site2, Guangdong Province
Henan Province Clinical Site1, Henan Province
Henan Province Clinical Site2, Henan Province
Jiangsu Province Clinical Site1, Jiangsu Province
Jiangsu Province Clinical Site3, Jiangsu Province
Jiangsu Province Clinical Site4, Jiangsu Province
Jiangsu Province Clinical Site5, Jiangsu Province
Jiangsu Province Clinical Site6, Jiangsu Province
Jiangxi Province Clinical Site2, Jiangxi Province
Jilin Province Clinical Site, Jilin Province
Liaoning Province Clinical Site, Liaoning Province
Shanxi Province Clinical Site, Shanxi Province
Tianjin Clinical Site1, Tianjin
Tianjin Clinical Site2, Tianjin
Zhejiang Province Clinical Site, Zhejiang Province
Zhengjiang Province Clinical Site, Zhengjiang Province
Aichi Clinical Site1, Nagoya
Aichi Clinical Site2, Nagoya
Chiba Clinical Site, Kamogawa
Ehime Clinical Site, Matsuyama
Ehime Clinicla Site, Matsuyama
Gifu Clinical Site, Ōgaki
Gunma Clinical Site, Ōta
Gunma Clinical Site, Takasaki
Hiroshima Clinical Site, Fukuyama
Hokkaido Clinical Site 3, Hakodate
Hokkaido Clinical Site 1, Sapporo
Hokkaido Clinical Site2, Sapporo
Hyogo Clinical Site, Akashi
Hyogo Clinical Site, Amagasaki
Hyogo Clinical Site, Nishinomiya
Ishikawa Clinical Site, Kanazawa
Iwate Clinical Site, Morioka
Kanagawa Clinical Site, Sagamihara
Kanagawa Clinical Site, Yokohama
Miyagi Clinical Site, Ōsaki
Nagano Clinical Site, Saku
Okayama Clinical Site, Kurashiki
Osaka Clinical Site, Hirakata
Osaka Clinical Site, Ōsaka-sayama
Osaka Clinical Site, Sakai
Osaka Clinical Site, Suita
Osaka Clinical Site, Takatsuki
Osaka Clinical Site, Toyonaka
Saitama Clinical Site, Hidaka
Saitama Clinical Site, Kitaadachi-gun
Shizuoka Clinical Site, Sunto-gun
Tochigi Clinical Site, Shimotsuke
Tokyo Clinical Site, Bunkyo-ku
Tokyo Clinical Site, Chuo-ku
Tokyo Clinical Site, Koto-ku
Tokyo Clinical Site, Shinjuku-ku
Chiba Clinical Site, Chiba
Fukuoka Clinical Site 1, Fukuoka
Fukuoka Clinical Site 2, Fukuoka
Gifu Clinical Site, Gifu
Hiroshima Clinical Site1, Hiroshima
Hiroshima Clinical Site2, Hiroshima
Hiroshima Clinical Site3, Hiroshima
Kochi Clinical Site, Kochi
Kumamoto Clinical Site, Kumamoto
Kyoto Clinical Site, Kyoto
Niigata Clinical Site, Niigata
Osaka Clinical Site1, Osaka
Osaka Clinical Site2, Osaka
Osaka Clinical Site3, Osaka
Osaka Clinical Site4, Osaka
Shizuoka Clinical Site, Shizuoka
Toyama Clinical Site, Toyama
Wakayama Clinical Site, Wakayama
Yamagata Clinical Site, Yamagata
Busan Clinical Site1, Busan
Busan Clinical Site2, Busan
Busan Clinical Site3, Busan
Daegu Clinical Site1, Daegu
Daegu Clinical Site2, Daegu
Daegu Clinical Site3, Daegu
Daejeon Clinical Site 1, Daejeon
Daejeon Clinical Site 2, Daejeon
Gwangju Clinical Site, Gwangju
Gyeonggi-do Clinical Site1, Gyeonggi-do
Gyeonggi-do Clinical Site2, Gyeonggi-do
Gyeonggi-do Clinical Site3, Gyeonggi-do
Gyeonggi-do Clinical Site4, Gyeonggi-do
Gyeonggi-do Clinical Site5, Gyeonggi-do
Jeollabuk-do Clinical Site, Jeollabuk-do
Seoul Clinical Site 8, Seoul
Seoul Clinical Site 9, Seoul
Seoul Clinical Site1, Seoul
Seoul Clinical Site2, Seoul
Seoul Clinical Site3, Seoul
Seoul Clinical Site4, Seoul
Seoul Clinical Site5, Seoul
Seoul Clinical Site6, Seoul
Seoul Clinical Site7, Seoul
Kaohsiung Clinical Site2, Kaohsiung City
Kaohsiung Clinical Site, Kaohsiung City
New Taipei Clinical Site, New Taipei City
Taichung Clinical Site, Taichung
Tainan Clinical Site2, Tainan City
Tainan Clinical Site, Tainan City
Taipei Clinical Site1, Taipei
Taipei Clinical Site2, Taipei
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Ono Pharmaceutical Co. Ltd
INDUSTRY